Evaluation of the tumor microenvironment in African American and non-Hispanic White patients with non-small cell lung cancer associated with PD-L1 expression or the presence of tertiary lymphoid structures.

Matthew Raymond Trendowski,Donovan Watza,Chrissy Lusk,Fulvio Lonardo,Valerie Ratliff,Angela Wenzlaff,Hirva Mamdani,Christine Neslund-Dudas,Julie Boerner,Ann G. Schwartz,Heather M Gibson

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.2627

IF: 45.3

2024-06-01

Journal of Clinical Oncology

Abstract:2627 Background: African Americans have higher incidence and mortality from lung cancer than non-Hispanic Whites, but investigations into differences in the tumor microenvironment and treatment response have been minimal. Due to the increasing utility of immunotherapy in the treatment of non-small cell lung cancer (NSCLC), we compared the immune cell composition and transcriptomic signature in the tumor microenvironment among African American and non-Hispanic White patients based on PD-L1 or tertiary lymphocyte structure (TLS) status to determine if there were differences of translational relevance. Methods: Using a cohort of 280 NSCLC patients from the INHALE study (non-Hispanic White: n = 155; African American: n = 125) with whole transcriptome microarray data, we determined the PD-L1 tumor proportion score (< 1% vs. ≥ 1%) and TLS status (presence/absence) within tumor tissue sections by immunohistochemistry. TLS were defined as dense aggregates of CD20 stained cells with a minimum diameter of 150 μm. Immune cell distribution within the tumor microenvironment was evaluated relative to differential gene expression. Results: Tumors from African Americans had a higher proportion of plasma cell signatures within the tumor microenvironment than tumors from non-Hispanic Whites. In addition, gene expression patterns in African American PD-L1 positive samples suggest these tumors contained significantly greater numbers of γδ T-cells and resting dendritic cells, along with fewer CD8 + T-cells compared to PD-L1 negative samples after adjusting for stage and histology. We also identified 22 genes that were differentially expressed between PD-L1 positive and negative tumors, along with 37 genes that were differentially expressed between TLS positive and negative tumors. Investigation of differential expression of B-cell/plasma cell related genes between the two patient populations revealed that four immunoglobulin genes in African Americans ( IGHA1, IGHD, IGKV2-29, and IGLL5) were associated with decreased mortality risk, while none of these genes were associated with overall survival in the non-Hispanic White population. Conclusions: In the first known race-stratified analysis of tumor microenvironment in lung cancer based on PD-L1 expression or TLS status, differences within the immune cell composition and transcriptomic signature were identified among non-Hispanic White and African American patients that may have therapeutic implications. Future investigation of these unique aspects within the tumor microenvironment will make advances in immunotherapy more equitable, thereby reducing the health disparities African Americans currently experience.

oncology